首页> 外文OA文献 >Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

【2h】

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

机译：悖论断裂带BRAF抑制剂对BRAF突变型结直肠癌中的ENCORAFENIB具有可比性效力和MAPK途径再激活

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Oliver J. Pickles; Aneta Drozd; Louise Tee; Andrew D. Beggs; Gary W. Middleton;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer [J] . Tabernero J., van Geel R., Bendell J. C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：晚期BRAF突变性结直肠癌患者中选择性BRAFV600抑制剂恩可拉非尼（LGX818）联合西妥昔单抗联合或不联合α-特异性PI3K抑制剂alpelisib（BYL719）的第一阶段研究
2. THE MAPK PATHWAY IS A THERAPEUTIC TARGET IN BRAF-MUTANT COLORECTAL CANCER [J] . Cancer discovery. . 2015,第11期

机译：MAPK通路是BRAF突变大肠癌的治疗靶标
3. Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations [J] . Corcoran R., Coffee E. M., Van Allen E., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：通过MAPK途径改变对BRAF突变型结直肠癌（CRC）患者进行RAF / EGFR或RAF / MEK联合抑制的临床获得性耐药
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Targeting the Hsp90 Molecular Chaperone and Resistant Pathways in BRAF-Mutant Melanoma [D] . Sanchez, Jaquelyn Nicole. 2020

机译：靶向BRAF-突变体黑素瘤的HSP90分子伴侣和抗性途径
6. Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer [O] . Oliver J. Pickles, Aneta Drozd, Louise Tee, 2020

机译：悖论断裂带BRAF抑制剂对BRAF突变型结直肠癌中的ENCORAFENIB具有可比性效力和MAPK途径再激活
7. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib [O] . Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, 2012

机译：EGFR介导的MAPK信号的再激活有助于BRAF-突变结直肠癌与vemureafenib的RAF抑制的不敏感性

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

著录项

相似文献

相关主题

期刊订阅